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An initial major adverse cardiac event (MACE) is an important
predictor of future cardiovascular events in patients with
chronic kidney disease (CKD). We sought to identify factors
influencing occurrence of initial MACE in new maintenance
hemodialysis patients without previous cardiac symptoms
during the predialysis phase of CKD. Among 112
participating patients with no predialysis cardiac history,
57 underwent coronary angiography, whereas the other
55 underwent stress thallium-201 single-photon emission
computed tomography within 1 month of beginning
hemodialysis to detect asymptomatic coronary artery disease
(CAD). In subsequent follow-up for a median of 24 months,
subjects experiencing an initial MACE were compared with
those who did not have such an event based on several
clinical parameters at the end of predialysis phase.
Asymptomatic CAD was present in 47 patients (42%), who
had a higher cumulative MACE rate, than subjects without
CAD (49 vs 3%, Po0.001). Multivariate Cox’s regression
analysis showed that three variables independently predicted
initial MACE: asymptomatic CAD (hazard ratio or HR, 611.31;
95% confidence interval or CI, 14.07–26549.23; Po0.001),
diabetes (HR, 20.41; 95% CI, 2.07–200.00; P¼ 0.010), and each
1 mg/l increment in C-reactive protein (CRP) (HR, 1.94; 95%
CI, 1.27–2.94; P¼ 0.002). In conclusion, detection of
asymptomatic CAD, presence of diabetes, or elevated CRP at
the end of the predialysis phase were significantly associated
with occurrence of an initial MACE in CKD patients starting
hemodialysis who had no CAD symptoms.
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Cardiovascular events caused by atherosclerotic coronary
artery disease (CAD) represent a major cause of mortality
and morbidity in patients with chronic kidney disease (CKD)
treated with maintenance hemodialysis, who have more than
10 times the risk of an initial episode characteristic of the
general population.1 Lindner et al. noted this pattern in their
early work, proposing that CAD was accelerated in popula-
tions undergoing long-term maintenance hemodialysis,2 as
accelerated atherosclerotic CAD was present in 62% of
patients with or without cardiac symptoms before initiating
hemodialysis,3 and in 53% of patients without these
symptoms.4 Further, cardiac events and overall mortality
after starting hemodialysis were significantly higher in
patients with than without CAD before the initiation of
hemodialysis.5,6 Indeed, coronary events and cardiac mortal-
ity occur with increased frequency in long-term maintenance
hemodialysis patients compared with general popula-
tion,1,2,7,8 leading to the misinterpretation that maintenance
hemodialysis itself accelerates coronary atherosclerosis and
increases CAD mortality. However, in other studies, longer
duration of hemodialysis therapy was not associated with an
increase in the risk of death from cardiovascular disease.9,10
Moreover, acute myocardial infarction was more likely to
occur within a short time after the initiation of dialysis than
after a prolonged course of dialysis therapy.11 These findings
suggest that coronary atherosclerosis is advanced and risk of
death from CAD already is high before starting maintenance
hemodialysis, which would seem unlikely in itself to
exacerbate atherosclerosis.
The issue above could be addressed by determining the
event rate of an initial major adverse cardiac event (MACE),
which is strongly associated with CAD, and the rate of
cardiac mortality in new hemodialysis patients lacking both
CAD symptoms and any evidence of deficient left ventricular
systolic function during the prior course of CKD. As
screening for CAD is not routinely carried out at the
initiation of hemodialysis, we compared baseline CAD and
other factors between patients with and without subsequent
de novo MACE occurring after beginning maintenance
hemodialysis.
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RESULTS
Patient characteristics
The study was conducted in 148 CKD patients (106 male and
42 female) at an age of 61712 years. Demographic, clinical,
and laboratory characteristics at the end of the predialysis
phase of CKD are described in Table 1. Prevalence of diabetes
as well as hemoglobin values was significantly higher in
asymptomatic patients with CAD than without CAD. No
significant differences were evident between groups in other
predialysis characteristics (P40.05). The prevalence of
asymptomatic CAD in CKD patients was 42% (47 of 112)
according to imaging performed within 1 month after the
initiation of hemodialysis. Although 24 patients had one-
vessel disease, 23 patients had multi-vessel disease.
Outcomes
Clinical outcomes at 24 months are summarized in Table 2.
Follow-up duration (median (range)) was 24 months (1–24).
Twenty-three asymptomatic patients (49%) with evidence of
CAD by coronary angiography (CAG) or stress thallium-201
single-photon emission computed tomography (SPECT),
two asymptomatic patients (3%) without CAD, and seven
patients of no screening CAD (20%) had MACE during
follow-up. Twenty-eight patients with acute cardiac event
successfully underwent coronary revascularization (percuta-
neous coronary intervention (PCI) in 26, coronary artery
bypass grafting in two). Five asymptomatic patients (11%)
with CAD died of cardiac causes; two died of acute
myocardial infarction as the first acute cardiac event, whereas
the remaining three underwent successful coronary revascu-
larization but died from cardiac causes (sudden cardiac arrest
in two and ischemic congestive heart failure in one) 12–15
months after the procedures. Two asymptomatic patients
with CAD had renal transplantation. Non-cardiac death
occurred in three asymptomatic patients with CAD (cancer
in two, pneumonia in one) and eight patients without CAD
(pneumonia in five, stroke in one, aortic dissection in one,
and peripheral artery disease in one).
Cumulative MACE event and all-cause mortality curves
are shown in Figure 1. Rates of MACE occurrence at 2 years
were 50 and 3% for asymptomatic patients with and without
CAD, respectively (Po0.001, log-rank test). Mortality rates
were not significantly different between asymptomatic
patients with and without CAD. Univariate Cox propor-
tional-hazards regression for the variables studied is shown in
Table 3. The presence of asymptomatic CAD, presence of
diabetes, increased serum C-reactive protein (CRP), and
increased hemoglobin were positively associated with acute
cardiac events during 2 years of follow-up. Multivariate Cox’s
proportional-hazards regression analysis was used to deter-
mine independent effects of asymptomatic CAD, diabetes,
CRP, hemoglobin, and albumin for a first acute cardiac event
after initiating hemodialysis. The presence of asymptomatic
CAD was a strong independent predictor for initial MACE
(hazard ratio or HR, 611.31; 95% confidence interval or CI,
14.07–26549.23, Po0.001). Other significant independent
Table 1 | Characteristics of study patients at the initiation
of hemodialysis
Asymptomatic
CAD
(n=47)
No
CAD
(n=65)
No CAD
screening
(n=36)
Age (years) 61711 61713 61714
Male gender, n (%) 34 (72) 47 (72) 25 (69)
Diabetes, n (%) 33 (70) 26 (40)w 17 (47)
Smoking habit, n (%) 22 (47) 22 (34) 16 (44)
History of hypertension, n (%) 42 (89) 53 (82) 32 (89)
GFR (ml/min/1.73m2) 6.971.6 6.172.3 5.972.6
BMI (kg/m2) 21.572.9 22.274.2 22.072.9
Mean BP (mmHg) 107720 110721 107717
Albumin (g/dl) 3.170.5 3.370.5ww 3.170.5
Total cholesterol (mg/dl) 188763 174757 186766
HDL cholesterol (mg/dl) 41716 41713 39711
Triglycerides (mg/dl) 137771 137773 134755
Lipoprotein (a) (mg/dl) 37721 31724 30712
Uric acid (mg/dl) 8.372.1 8.072.0 8.372.1
Calcium (mg/dl) 8.271.0 7.971.0 8.171.0
Phosphate (mg/dl) 5.971.7 6.371.7 6.672.2
CRP (mg/l) 4.273.8 3.073.8 2.873.2
Hemoglobin (g/dl) 8.871.4 7.871.4w 7.771.6
Fibrinogen (mg/dl) 4677122 4367160 411793
LVEF % 61713 63715 66710
CAD
One-vessel (%) 24 (51)
Multi-vessel (%) 23 (49)
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; CAD, coronary
artery disease; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LVEF,
left ventricular ejection fraction.
wPo0.005 compared with patients with CAD. wwP=0.069 compared with asympto-
matic patients with CAD.
Table 2 | End points and intervention treatments of study
patients
Asymptomatic
CAD
(n=47)
No
CAD
(n=65)
No CAD
screening
(n=36)
Primary end point
Major adverse cardiac event 23 (49%) 2 (3%) 7 (20%)
Myocardial infarction 5 (11%) 1 (2%) 2 (6%)
Unstable angina 16 (33%) 1 (2%) 4 (11%)
Acute heart failure 2 (4%) 0 1 (3%)
Interventional treatment 21 (45%) 2 (3%) 5 (14%)
PCI 19 (41%) 2 (3%) 5 (14%)
CABG 2 (4%) 0 0
Secondary end point
All cause of death 8 (17%) 8 (12%) 5 (14%)
Cardiac death 5 (11%) 0 3 (9%)
Myocardial infarction 2 (4%) 0 2 (6%)
Sudden cardiac arrest 2 (4%) 0 1 (3%)
Ischemic heart failure 1 (2%) 0 0
Non-cardiac death 3 (6%) 8 (12%) 2 (6%)
Cancer 2 (4%) 0 1 (3%)
Pneumonia 1 (2%) 5 (8%) 1 (3%)
Stroke 0 1 (2%) 0
Aortic dissection 0 1 (2%) 0
Peripheral artery disease 0 1 (2%) 0
CABG, coronary artery bypass grafting; CAD, coronary artery disease; PCI,
percutaneous coronary intervention.
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predictors for an initial MACE included high CRP and
presence of diabetes (Table 4).
Receiver operating characteristic analysis
The area under the receiver operating characteristic (ROC)
curve was 0.778 (95% CI 0.678–0.878, Po0.001; Figure 2).
The best cutoff point of CRP was determined to be 3.5 mg/l
(sensitivity 75%, specificity 76%).
Validation of risk factors for future MACE
All study patients were classified into four subgroups
according to two independent risk factors, asymptomatic
CAD and CRP, in separate analyses of diabetic and non-
diabetic patients (Figure 3). Group 1 was defined by the
absence of CAD with CRP o3.5 mg/l; group 2, absence of
CAD with CRP X3.5 mg/l; group 3, presence of asympto-
matic CAD with CRP o3.5 mg/l; and group 4, presence of
asymptomatic CAD with CRP X3.5 mg/l. Among diabetic
patients, risk of MACE in group 4 (93%) was significantly
higher than in group 1 (0%, Po0.001), group 2 (22%,
P¼ 0.001), or group 3 (44%, P¼ 0.005). Risk of future
MACE did not differ between groups 1 and 2 (P¼ 0.068) or
between groups 1 and 3 (P¼ 0.067). For non-diabetic
patients, risk in group 4 (75%) was significantly higher than
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Figure 1 | Comparison of cumulative rate of initial MACE and all
cause of mortality between patients with asymptomatic CAD and
without CAD. (a) Asymptomatic patients with CAD had a signifi-
cantly higher MACE rate than patients without CAD (Po0.0001,
log-rank test). (b) Mortality rates were not significantly different
between asymptomatic patients with and without CAD.
Table 3 | Unadjusted univariate HRs for the first major
adverse cardiac event after the initiation of hemodialysis
Units of increase HR (95% CI) P-value
CAD 0=no; 1=yes 30.19 (6.60–137.97) o0.001
One-vessel 0=normal; 1=yes 10.50 (1.94–56.57) 0.007
Multi-vessel 0=normal; 1=yes 89.25 (1.94–56.57) o0.001
Diabetes 0=no; 1=yes 8.23 (2.29–29.53) 0.002
CRP 1 mg/l 1.24 (1.08–1.41) 0.002
Hemoglobin 1 g/dl 1.43 (1.04–1.96) 0.028
Albumin 1 mg/dl 0.45 (0.17–1.11) 0.083
Lipoprotein (a) 1 mg/dl 1.02 (0.99–1.04) 0.131
Phosphate 1 mg/dl 0.83 (0.61–1.13) 0.230
GFR 1 ml/min/1.73 m2 1.14 (0.92–1.41) 0.240
Calcium 1 mg/dl 1.30 (0.81–2.07) 0.279
HDL cholesterol 1 mg/dl 0.99 (0.94–1.02) 0.290
Male gender 0=no; 1=yes 1.33 (0.47–3.71) 0.310
Age 1 yr 1.02 (0.98–1.06) 0.315
Fibrinogen 1 mg/dl 0.99 (0.98–1.01) 0.400
Hypertension 0=no; 1=yes 1.92 (0.39–9.21) 0.416
BMI 1 kg/m2 0.93 (0.98–1.04) 0.479
Smoking habit 0=no; 1=yes 1.20 (0.45–3.18) 0.713
LVEF 1% 1.00 (0.97–1.03) 0.845
Triglycerides 1 mg/dl 1.00 (0.99–1.01) 0.865
Mean BP 1 mmHg 1.01 (0.98–1.03) 0.886
Total cholesterol 1 mg/dl 1.00 (0.99–1.01) 0.995
BMI, body mass index; BP, blood pressure; CAD, coronary artery disease;
CI, confidence interval; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL,
high density lipoprotein; HR, hazard ratio; LVEF, left ventricular ejection fraction.
Table 4 | Unadjusted stepwise multivariate HRs for a
first major adverse cardiac event after the initiation of
hemodialysis
Units of increase HR (95% CI) P-value
CAD 0=no; 1=yes 611.31 (14.07–26 549.23) o0.001
One-vessel 0=normal; 1=yes 191.23 (12.93–12 450.70) 0.007
Multivessel 0=normal; 1=yes 2200.16 (24.62–196 613.30) o0.001
Diabetes 0=no; 1=yes 20.41 (2.07–200.00) 0.010
CRP 1 mg/l 1.94 (1.27–2.94) 0.002
CAD, coronary artery disease; CI, confidence interval; CRP, C-reactive protein;
HR, hazard ratio.
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Figure 2 | ROC curve for CRP as a predictor of an initial MACE.
Data for CRP resulting in a cutoff value of 3.5 mg/l were
obtained from 112 patients with and without CAD.
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in group 1 (0%, Po0.001), group 2 (0%, Po0.001), or group
3 (0%, P¼ 0.003).
DISCUSSION
Results of the present study indicated (1) a prevalence of
asymptomatic CAD (42%) in CKD patients according to
imaging assessment within 1 month after the initiation of
hemodialysis; (2) early occurrence of all initial MACE
associated with atherosclerotic coronary disease in asympto-
matic CAD patients within 1 year after the initiation of
hemodialysis; (3) MACE occurrence during the 2-year
follow-up in 23 asymptomatic patients with CAD vs two
patients without CAD; and (4) the identification of
independent predictors of initial MACE including elevated
CRP at the end of the predialysis phase of CKD, presence of
asymptomatic CAD based on early CAG or stress thallium-
201 SPECT, and presence of diabetes. Whether maintenance
hemodialysis in itself promotes progression of coronary
atherosclerosis remains unclear. Our findings may shed some
new light on the issue. We hypothesized that metabolic
uremic abnormalities rather than hemodialysis per se are the
main cause of atherosclerosis progression in end-stage renal
disease patients. This hypothesis could be tested by compar-
ing incidence of initial coronary events between periods
before and after starting hemodialysis. We chose another test,
aiming to minimize biases and facilitate the interpretation of
results by studying consecutive new hemodialysis patients
with no history of coronary symptoms, comparing subgroups
with and without imaging findings of asymptomatic CAD at
the start of the observation period. Over 2 years of
prospective follow-up, the occurrence rate of an initial acute
cardiac event was 3% in the 65 asymptomatic patients
without CAD. This was significantly lower than the 49% rate
seen in the 47 asymptomatic patients showing CAD.
Interestingly, all initial acute cardiac events in patients with
CAD occurred within 1 year; in the second year of follow-up,
no initial acute cardiac events were observed. On the other
hand, patients without CAD had no initial acute cardiac
events within the first year of hemodialysis. These results
suggested that hemodialysis in itself had little effect on
coronary atherosclerosis at least in end-stage renal disease
patients with low apparent atherogenic risk. On the other
hand, it remains the possibility that hemodialysis plays a role
of accelerating progression of coronary atherosclerosis or
inducing acute cardiac events in those with higher athero-
genic risk, especially in its early phase. This is a hypothetical
situation, as they might not survive a year without dialysis.
Clearly, hemodialysis is a first priority for end-stage renal
disease patients; however, an assessment of CAD status before
or soon after the initiation of hemodialysis may be helpful in
two senses. First, it would inform the treating physician of a
substantial excess risk and may lead to measures that would
prevent a MACE. Secondly, it may lead to a better under-
standing of why the high rate of MACE that occurs in the
first year of hemodialysis is so high in asymptomatic
CAD patients.
Duration of maintenance hemodialysis therapy has been
reported not to increase the risk of cardiovascular death.11
Moreover, arterial wall thickness12 and stiffness13 have been
found to show no significant relationship with duration of
hemodialysis. These findings are in keeping with our
hypothesis that hemodialysis does not promote progression
of atherosclerosis. Shoji et al.14 clearly demonstrated that
uremic patients about to start hemodialysis had significantly
increased aortic pulse wave velocity, comparable to that in
patients receiving maintenance hemodialysis treatment. They
concluded that uremia-related metabolic abnormalities
rather than hemodialysis worsened aortic stiffness. Although
we did not examine possible vessel wall effects of hemo-
dialysis in this study, our observations suggested that hemo-
dialysis can slow the progression of coronary atherosclerosis
in asymptomatic CAD, which had been accelerated by
uremia-related metabolic abnormalities before the initiation
of hemodialysis.
Predictors of an initial acute cardiac event after starting
hemodialysis were defined in our study. Mortality from
cardiac causes after acute myocardial infarction among
hemodialysis patients has been reported to amount to
70.2% at 5 years.11 Moreover, recent morphologic studies
designed to examine risk factors for cardiovascular events
have implicated a history of CAD and/or congestive heart
failure.1,2,7,8 Identification of a history of CAD as a powerful
Diabetic patients
Nondiabetic patients
Group 1
Group 3 Group 4
No CAD
and
and
CRP<3.5 mg/l
CRP<3.5 mg/l
Group 2
No CAD
and
and
CRP3.5 mg/l
CRP3.5 mg/l
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Figure 3 | Occurrence of an initial MACE after initiating
maintenance hemodialysis according to three risk factors:
diabetes, CAD, and CRP.
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predictor of future cardiovascular events in hemodialysis
patients underscores the importance of determining risk
factors for initial acute cardiac events. In the present study,
we therefore examined such risk factors in hemodialysis
patients with no history of symptomatic cardiac disease. The
prevalence of asymptomatic CAD diagnosed by CAG or stress
thallium-201 SPECT was 42% among all study patients, a
somewhat lower percentage than that found in a previous
study from our group (63%).3
The reason for this difference was that 42% of patients in
the previous study had a history of symptomatic cardiac
disease at baseline, including acute cardiac events.
Hemoglobin values were significantly higher in asympto-
matic patients with than without CAD. Although partial
anemia correction has been found to significantly increase
exercise tolerance, maximum exercise-induced ST depression
decreased significantly with partial correction in hemodialysis
patients with CAD.15 These results suggested that the
improvement in maximum oxygen supply exceeded the
increase in maximum myocardial oxygen demand imposed
by longer exercise. Therefore, relatively high hemoglobin
concentrations might have helped to clinically mask CAD
symptoms during the predialysis period of CKD.
An initial MACE occurred within 1 year after the
initiation of hemodialysis in 49% of patients whose imaging
showed CAD. This rate was higher than the rates of life-
threatening (9% per year) or total cardiac events (38% per
year) in asymptomatic non-CKD patients with diabetes
mellitus who had abnormal SPECT.16 Sudden hemodynamic
changes are thought to influence this result. During the few
months after the initiation of hemodialysis, myocardial
oxygen demand is suddenly increased as renal anemia
progresses and the circulation must adapt to an arteriovenous
fistula.17,18 In contrast, 51% of asymptomatic patients with
CAD and 97% of patients without CAD had remained free
from MACE at 24 months after the initiation of hemodia-
lysis. Common factors in patients without MACE were the
absence of diabetes and CRP below 3.5 mg/l. Hemoglobin
concentration was not an independent risk factor for future
MACE, despite a significant linear relationship between these
factors, as a significant relationship was seen between
hemoglobin concentration and absence of CAD. Potential
causes of chronic inflammation in hemodialysis patients, a
major contributor to de novo MACE according to our study,
may include dialyzer incompatibility and dialysate contami-
nation.19,20 Although encounters with such inflammatory
stimuli are increased in patients undergoing short daily
hemodialysis beyond those using conventional hemodialysis
schedules, CRP concentrations were found to decrease
significantly from baseline at 12 months after initiating short
daily hemodialysis.21 Moreover, Pupim et al.22 found that
maintenance hemodialysis in itself did not significantly
influence CRP. Further, the HEMO study7 demonstrated no
decrease in risk of death from all causes when dialysis
membrane flux was increased. In our study, which appeared
to exclude a major influence of hemodialysis, a de novo acute
cardiac event in the years just following initiation of
hemodialysis was predicted by three variables assessed at
the end of the predialysis phase of CKD.
In the present study, presence of asymptomatic CAD,
diabetes, or CRP elevation at the end of the predialysis phase
of CKD significantly increased the likelihood of an initial
MACE after starting hemodialysis. Increased CRP has been
reported to independently predict acute coronary syndrome
in the general population.23 Further, baseline CRP concen-
tration is a strong independent predictor of risk of future
myocardial infarction, stroke, peripheral vascular disease, and
vascular death among healthy men and women without
known vascular disease.24,25 CRP is an activator of blood
monocytes and vessel wall endothelial cells,26,27 and may
participate directly in the process of atherothrombosis. In
patients with diabetes, CRP effect may be compounded with
macrophage infiltration and thrombus formation, which
increase in advanced coronary plaques with unstable
angina.28 Diabetic atherosclerosis have been identified,
including adventitial inflammation29 and neovascularization
arising from vasa vasorum leading to intraplaque hemor-
rhage, macrophage activation, and atherosclerotic plaque
growth resulting in progressive plaque destabilization,30 such
inflammatory microangiopathic processes are independently
associated with plaque rupture, leading to coronary throm-
bosis.31 Zoccali et al.32 recently demonstrated that patients
with low CRP (o3.4 mg/l) had significantly lower overall
cardiovascular mortality than those with high CRP. Our
present data made clear that CRP could predict future MACE
in hemodialysis patients. These results indicate that inflam-
mation is involved in progression of atherosclerosis in
dialysis patients.
In CKD patients with CAD, interventional treatment has
been shown to decrease symptoms more effectively than
conservative medical treatment.33 However, in the general
population with stable CAD and no recent myocardial
infarction, PCI did not offer any benefit in terms of death,
myocardial infarction, or need for subsequent revasculariza-
tion compared with conventional medical treatment.34 In our
study, 51% of hemodialysis patients with asymptomatic CAD
had no MACE during the 2 years of follow-up. Although the
restenosis rate was found to be significantly lower in
hemodialysis patients treated by coronary stenting as
opposed to balloon atherectomy, stenting had less impact
on likelihood of subsequent need for revascularization.35
These studies suggested that in hemodialysis patients with
stable or asymptomatic CAD and good left ventricular
function, PCI did not confer any clear benefit beyond over
conservative medical treatment. At the same time, early fear
of an increased need for revascularization after PCI probably
is unwarranted. PCI may be indicated in hemodialysis
patients with acute coronary events, a history of myocardial
infarction with or without revascularization, or more than
two of three risk factors for future acute cardiac event,
including the presence of CAD, diabetes, and CRP above
3.5 mg/l.
1146 Kidney International (2006) 70, 1142–1148
o r i g i n a l a r t i c l e H Hase et al.: Initial cardiac events in new hemodialysis
In conclusion, our present study clearly confirmed the
predictive importance of asymptomatic CAD, at the initia-
tion of hemodialysis, elevated CRP at the same time point,
and presence of diabetes concerning likelihood of a de novo
acute cardiac event in patients initiating maintenance
hemodialysis. Our results indicated that screening for CAD
at the initiation of hemodialysis is clinically useful for
predicting future risk of acute cardiac event in new
hemodialysis patients with normal left ventricular systolic
function and without CAD symptoms.
MATERIALS AND METHODS
Study design and cohort eligibility
Eligibility criteria for our study were as follows: end-stage renal
disease resulting from any form of CKD; hemodialysis therapy being
initiated at our hospital; absence of symptomatic CAD or coronary
events in the predialysis phase of CKD; normal values for
parameters of systolic cardiac function; and screening for CAD by
CAG or thallium-201 SPECT including pharmacologic stress,
performed within 1 month of the first dialysis session. Our study
protocol for CAD screening in new hemodialysis patients was
changed in January 2000 from CAG to thallium-201 SPECT using
pharmacologic stress. In our hospital, 252 patients with CKD began
maintenance hemodialysis between January 1993 and December
2003. Among these 252 consecutive patients, 20 with a history of
myocardial infarction, seven with a history of coronary revascular-
ization, 59 with a history of congestive heart failure, 36 with typical
symptoms of stable angina, and 45 with decreased left ventricular
ejection fraction (o50%) were excluded from study. Among the
remaining 148 patients, 57 gave written informed consent to
undergo CAG, whereas 55 other patients gave written informed
consent to undergo thallium-201 SPECT, including pharmacologic
stress to detect asymptomatic CAD. Either study was performed
within 1 month of the initiating maintenance hemodialysis. The
remaining 36 patients declined to undergo any screening for CAD
(Figure 4).
Baseline hematologic and biochemical examinations were
performed just before the initial hemodialysis session. CRP
concentrations were measured using a turbidimetric method.
Glomerular filtration rate was estimated by the modification of
diet in renal disease formula. Echocardiograms were performed just
after hemodialysis when the patient’s symptoms were grade 1
according to New York Heart Association criteria, aiming to avoid
underestimation of left ventricular function as a result of volume
overload. Performance of CAG or pharmacologic-stress thallium-
201 SPECT in asymptomatic CKD patients had received prior
approval by the ethics committee at our institution (Toho University
investigation number 16-011).
Definitions of CAD and ATP stress thallium-201 SPECT
Clinically significant asymptomatic CAD was defined as present
when narrowing exceeded 75% of the uninvolved reference segment
diameters in patients undergoing CAG, or when reversible
myocardial perfusion defects were seen in patients with pharmaco-
logic-stress thallium-201 SPECT. Pharmacologic stress testing was
induced by intravenous infusion of adenosine triphosphate (ATP)
after a 3-h fast. One vein in each upper limb was used to ensure that
ATP infusion and thallium-201 injection were administered via
different sites. An automatic infusion pump was used to deliver ATP
(0.16 mg/kg/min) over 6 min. Electrocardiographic and hemo-
dynamic monitoring were performed, and symptoms related to
ATP infusion were recorded.
Thallium-201 (111 MBq) was injected 5 min after the initiation
of ATP infusion. Stress cardiac scintigraphic images were acquired
5–10 min after the end of the infusion, and 4 h later for the rest-
redistribution phase. The studies consisted of 33 projections.
Myocardial perfusion imaging was performed with a rotating
three-headed g camera (Multispect 3; Siemens Medical Solutions,
Chicago, IL, USA) equipped with low-energy cardiofocal collimators
and interfaced with a computer (ICON; Siemens Medical Solu-
tions). Oblique tomograms reoriented in short, horizontal, and long
axes were obtained.
Outcome
The primary end point of interest was an initial onset of MACE.
MACE was defined as (1) ST-elevation acute myocardial infarction
(requiring new ST-segment elevation exceeding 1 mm in any lead
and symptoms suggesting acute ischemia, plus a total creatine kinase
concentration in serum of at least three times the upper limit of
normal and two times the patient’s baseline concentration); (2) no
ST-elevation acute myocardial infarction (requiring symptoms
suggesting acute ischemia plus a total creatine kinase concentration
in serum of at least three times the upper limit of normal and two
times the patient’s baseline concentration); (3) unstable angina
(Braunwald class III unstable angina with one or more episodes of
acute ischemic symptoms at rest within the preceding 48 h,
requiring emergency admission and revascularization); or (4) acute
heart failure without typical chest pain, nonetheless attributable to
CAD with coronary stenosis exceeding 90% or intracoronary
thrombus formation demonstrated by CAG. CAG was performed
in all patients with MACE at the time of the event. Myocardial
revascularization was performed when significant coronary stenosis
and morphologic indications were confirmed by CAG. Acute
myocardial infarction and unstable angina were recorded retro-
spectively. A secondary end point of interest was death from all
causes. Patients were followed up for 24 months, until death from
All eligible patients with CKD starting RRT during a 10-year period
Excluded
Asymptomatic CKD patients enrolled
27: Myocardial infarction/coronary revascularization
59: Congestive heart failure
36: Stable angina
45: Low cardiac output (LVEF<50%)
36
CAD screening declined
112
148
CAG: 57
SPECT: 55
65
No CADAsymptomatic CAD
Final screening groups for CAD
252
47
Figure 4 | Design of the study. CKD, chronic kidney disease; RRT,
renal replacement therapy; LVEF, left ventricular ejection fraction;
CAG, coronary angiography; SPECT, single-photon emission
computed tomography; CAD, coronary artery disease.
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any cause or renal transplantation. Patients were personally
interviewed during follow-up period. All surgical or percutaneous
myocardial revascularization procedures as well as all hospitaliza-
tions were recorded prospectively during follow-up.
Statistical analysis
Quantitative variables with normal distribution are presented as
mean7s.d. A w2 test for categorical variables and an unpaired t-test
for continuous variables were used to evaluate differences between
patients with CAD and without CAD. Correlations between two
variables were examined by linear regression analysis in asympto-
matic patients with and without CAD, excluding the patients
without CAD screening. Independent association between variables
was evaluated by stepwise multiple regression analysis using a time-
dependent model in asymptomatic patients with and without CAD,
excluding the patients without CAD screening. Usefulness of CRP to
identify MACE was tested by analysis of ROC curves, whereas the
diagnostic value of CRP was compared between curves by applying
Wilcoxon’s rank-sum statistics to the areas under the curves. A best
cutoff value of CRP was defined retrospectively based upon analysis
of the ROC curves. P-values less than 0.05 were considered
indicative of statistical significance. Statistical analysis was per-
formed with commercially available software for the Windows
operating system (SPSS 11.0; SPSS, Chicago, IL, USA).
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